You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Dr Reddys launches Remdesivir in India

Capital Market 

The drug major on Wednesday (9 September) announced the launch of Remdesivir, under a brand name Redyx in India.

The launch is part of the licensing agreement with Gilead Sciences, Inc. that grants Dr. Reddy's the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms. Dr. Reddy's Redyx is available in strength of 100 mg vial.

M V Ramana, chief executive officer, branded markets (India and emerging markets), Dr. Reddy's Laboratories, said "We will continue our efforts to develop products that address significant unmet needs of patients. The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from Covid-19 in India.

Further, Dr. Reddy's Laboratories also announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren Arthritis Pain in the US market. The solution is used for the temporary relief of arthritis pain in upper and lower body areas.

Voltaren Arthritis Pain brand had total US retail sales of approximately $44 million since launch in May 2020 according to IRI.

Shares of Dr. Reddy's Laboratories were up 0.38% at 4364.40. The stock has surged 74.74% from it 52-week low of Rs 2497.60 hit on 19 March 2020. It hit a 52-week high of Rs 4754.30 on 10 August 2020.

Dr. Reddy's Laboratories is an India-based pharmaceutical company. Through its three businesses - pharmaceutical services and active ingredients, global generics and proprietary products - the company offers a portfolio of products and services, including active pharmaceutical ingredients (API), custom pharmaceutical services (CPI), generics, biosimilars, differentiated formulations and new chemical entities.

The drug major's consolidated net profit skid 12.11% to Rs 594.60 crore on 14.93% jump in revenue from operations to Rs 4,417.50 crore in Q1 June 2020 over Q1 June 2019.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 09 2020. 10:44 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU